Digital health has the potential to significantly improve cancer care and outcomes by enabling more precise diagnosis and treatment, improving patient engagement and monitoring, and facilitating research and data sharing. Digital health tools in oncology include telemedicine for remote consultations, mobile apps for patient self-monitoring, wearables for real-time data tracking, and artificial intelligence for image analysis and treatment planning. These tools can help oncologists make more informed decisions, tailor treatments to individual patients, and improve patient adherence and quality of life. Digital health also allows for better integration and analysis of large-scale data, enabling more effective research and development of new therapies. Despite the potential benefits, there are also challenges to the widespread adoption of digital health in oncology, including regulatory and privacy concerns, data interoperability issues, and the need for clinician training and support.
Know anyone building innovative solutions that belong in this 'Digital Health in Oncology'?
CHI’s Immuno-Oncology Summit Europe returns to London for 3 days of discussions and networking around the recent advances in immuno-oncology therapies.
CHI's 7th Annual Immuno-Oncology Summit Europe returns to London's Hilton Canary Wharf for three packed days of science and technology discussions on the recent advances in the development of promising immuno-oncology therapies.
The Summit, scheduled for 20-22 June 2023, comprises 4 conference programs, from strategies on Modulating the Tumour Microenvironment; to various treatment modalities including Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and Gamma Delta Immunotherapy.
Highlights include a Plenary Keynote Session featuring 4 distinguished Keynote Speakers; engaging Breakout Discussions that bring peers together to chat about current trends and latest developments on the most pressing or contentious topics; a balanced faculty of industry and academia speakers; and an Exhibit Hall showcasing the technology leaders in the IO space.
Join us at the Immuno-Oncology Summit Europe 2023 to meet peers, exchange ideas, and find collaborators to accelerate your next IO program.
As the incidence of melanoma continues to rise rapidly in the United States and around the world, the need to educate clinicians from various specialties on the disease also increases. During this course nationally recognized experts will present information on prevention, risk assessment, early detection, genetic factors, and current and future treatment choices for melanoma patients. Issues concerning surgical management, adjuvant therapy, advanced disease therapy, and personalizing the course of treatment for individual patients will also be discussed. This course is designed to provide information that will help clinicians in their decision making regarding these difficult patient problems. The course will be taught by a wide range of experts as this most serious of skin cancers will require multidisciplinary efforts to conquer.
Expanse Oncology is a natural extension and evolution of our successful Oncology product, redesigned with the personalization and mobility of Expanse’s web-based physician tools. As part of our integrated EHR, Expanse Oncology gives clinics and hospitals a singular patient record with access to all the information needed to navigate complex medication treatment plans. Clinicians benefit from embedded decision support as well as expert-based templates and protocols from gold-standard industry resources. From diagnosis to survivorship, Expanse Oncology automates both practice and scheduling workflows to ensure a positive patient experience.
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our